Edwards Lifesciences Corporation
EWNYSEHealthcare● Active
$85.85
$-0.11(-0.13%)
Market Cap$49.4B
P/E Ratio—
52W High$89.48
52W Low$72.3
Edwards Lifesciences Corporation (EW) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EW · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| Depreciation & Amort. | $0.16B | $0.16B | $0.14B | $0.14B | $0.13B |
| Stock-Based Comp. | $0.16B | $0.16B | $0.14B | $0.13B | $0.11B |
| Change in Working Capital | $0.15B | ($0.26B) | ($0.53B) | ($0.42B) | $0.15B |
| Net Cash from Operations | $1.60B | $0.54B | $0.90B | $1.22B | $1.73B |
| Investing Activities | |||||
| Capital Expenditure | ($0.26B) | ($0.25B) | ($0.27B) | ($0.26B) | ($0.33B) |
| Purchases of Investments | ($3.14B) | ($0.95B) | ($0.11B) | ($0.78B) | ($1.89B) |
| Sales of Investments | $2.88B | $0.86B | $0.72B | $1.36B | $0.53B |
| Net Cash from Investing | ($0.71B) | $2.31B | $0.17B | $0.25B | ($1.72B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.89B) | ($1.16B) | ($0.88B) | ($1.73B) | ($0.51B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Cash from Financing | ($0.96B) | ($0.98B) | ($0.71B) | ($1.58B) | ($0.36B) |
| Free Cash Flow | |||||
| Free Cash Flow | $1.33B | $0.29B | $0.63B | $0.95B | $1.40B |
| FCF Margin %(computed) | 22.00% | 5.33% | 12.56% | 17.71% | 26.80% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Edwards Lifesciences Corporation data
About Edwards Lifesciences Corporation (EW) Cash Flow Statement
Edwards Lifesciences Corporation generated operating cash flow of $1.60B and free cash flow of $1.33B for 2025 — a FCF margin of 22.00%. Capital expenditure was ($0.26B).
Frequently asked questions
EW · 4 questionsEdwards Lifesciences Corporation generated free cash flow of $1.33B for 2025, up 360.5% year-over-year.
EW free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10